Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Open accessAbstract
BACKGROUNDNirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (M pro ) inhibitor with potent pan-human-coronavirus activity in vitro. METHODSWe conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days.Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated. RESULTSA total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group).In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths.Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%).All 13 deaths occurred in the placebo group.The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log 10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms.The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%).Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo. CONCLUSIONSTreatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns.(Supported by Pfizer; ClinicalTrials.govnumber, NCT04960202.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Paxlovid is highly effective at preventing progression to severe COVID-19 in symptomatic patients.
“Paxlovid was shown to be highly effective at preventing progression to severe COVID-19 in symptomatic patients105.”
From Advances in covalent drug discovery (2022) · cites this paper as [105]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016 · see citing works
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449 · see citing works
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528 · see citing works
Docherty, A. B., Harrison, E. M., Green, C. A., Hardwick, H. E., Pius, R., Norman, L., Holden, K. A., Read, J. M., Dondelinger, F., Carson, G., et al. (2020) · BMJ · doi:10.1136/bmj.m1985 · Cited by 3,481 · see citing works
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311 · see citing works
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310 · see citing works
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · see citing works
Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J., Li, Q., Jiang, C., Zhou, Y., Liu, S., et al. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.04.021 · Cited by 2,074 · see citing works
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
Owen, D. R., Allerton, C. M. N., Anderson, A. S., Aschenbrenner, L., Avery, M., Berritt, S., Boras, B., Cardin, R. D., Carlo, A., Coffman, K. J., et al. (2021) · Science · doi:10.1126/science.abl4784 · Cited by 2,033 · see citing works
Coronavirus Main Proteinase (3CL pro ) Structure: Basis for Design of Anti-SARS Drugs
Anand, K., Ziebuhr, J., Wadhwani, P., Mesters, J. R., & Hilgenfeld, R. (2003) · Science · doi:10.1126/science.1085658 · Cited by 1,734 · see citing works
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
Gottlieb, R., Vaca, C., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., Ryan, P., Nielsen, B. U., Brown, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2116846 · Cited by 1,230 · see citing works
Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086 · see citing works
Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases
Yang, H., Xie, W., Xue, X., Yang, K., Ma, J., Liang, W., Zhao, Q., Zhou, Z., Pei, D., Ziebuhr, J., et al. (2005) · PLoS Biology · doi:10.1371/journal.pbio.0030324 · Cited by 722 · see citing works
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
Dougan, M., Nirula, A., Azizad, M., Mocherla, B., Gottlieb, R. L., Chen, P., Hebert, C., Perry, R., Boscia, J., Heller, B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2102685 · Cited by 663 · see citing works
From SARS to MERS : crystallographic studies on coronaviral proteases enable antiviral drug design
Hilgenfeld, R. (2014) · FEBS Journal · doi:10.1111/febs.12936 · Cited by 661 · see citing works
Kim, L., Garg, S., O’Halloran, A., Whitaker, M., Pham, H., Anderson, E. J., Armistead, I., Bennett, N. M., Billing, L., Como-Sabetti, K., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1012 · Cited by 649 · see citing works
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T. D., Ali, S., Gao, H., Bhore, R., Xiao, J., Hooper, A. T., Hamilton, J. D., Musser, B. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108163 · Cited by 641 · see citing works
Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir
Sevrioukova, I. F., & Poulos, T. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010693107 · Cited by 288 · see citing works
Thakur, B., Dubey, P., Benitez, J., Torres, J. P., Reddy, S., Shokar, N., Aung, K., Mukherjee, D., & Dwivedi, A. K. (2021) · Scientific Reports · doi:10.1038/s41598-021-88130-w · Cited by 284 · see citing works
Covid-19: What new variants are emerging and how are they being investigated?
Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n158 · Cited by 150 · see citing works
Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report
Ning, L. G., Liu, L., Li, W., Liu, H., Wang, J., Yao, Z., Zhang, S., Zhao, D., Nashan, B., Shen, A., et al. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15897 · Cited by 74 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [1]Center for Systems Science and Engineering. COVID-19 Dashboard. Johns Hopkins University (https://coronavirus.jhu.edu/map.html). PMC9432867 36057267
- [10]National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines (https://www.covid19treatmentguidelines.nih.gov/). 34003615
Cited by
Sorted by citations
Markov, P. V., Ghafari, M., Beer, M., Lythgoe, K., Simmonds, P., Stilianakis, N. I., & Katzourakis, A. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00878-2 · Cited by 1,179 · see citing works
Advances in covalent drug discovery
Boike, L., Henning, N. J., & Nomura, D. K. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00542-z · Cited by 823 · see citing works
Therapeutic strategies for COVID-19: progress and lessons learned
Li, G., Hilgenfeld, R., Whitley, R. J., & Clercq, E. D. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00672-y · Cited by 691 · see citing works
Najjar‐Debbiny, R., Gronich, N., Weber, R., Khoury, J., Amar, M., Stein, N., Goldstein, L. H., & Saliba, W. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac443 · Cited by 522 · see citing works
Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Iketani, S., Mohri, H., Culbertson, B., Hong, S. J., Duan, Y., Luck, M. I., Annavajhala, M. K., Guo, Y., Sheng, Z., Uhlemann, A., et al. (2022) · Nature · doi:10.1038/s41586-022-05514-2 · Cited by 498 · see citing works
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449 · see citing works
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
Arbel, R., Sagy, Y. W., Hoshen, M. B., Battat, E., Lavie, G., Sergienko, R., Friger, M. D., Waxman, J. G., Dagan, N., Balicer, R. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204919 · Cited by 359 · see citing works
Association of Treatment With Nirmatrelvir and the Risk of Post–COVID-19 Condition
Xie, Y., Choi, T., & Al‐Aly, Z. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.0743 · Cited by 352 · see citing works
Karki, R., Lee, S., Mall, R., Nagakannan, P., Wang, Y., Sharma, B. R., Malireddi, R. K. S., Yang, D., Trifkovic, S., Steele, J. A., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abo6294 · Cited by 348 · see citing works
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Hu, Y., Lewandowski, E. M., Tan, H., Zhang, X., Morgan, R. T., Zhang, X., Jacobs, L. M. C., Butler, S. G., Gongora, M. V., Choy, J. S., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.3c00538 · Cited by 348 · see citing works
Nirmatrelvir Plus Ritonavir: First Approval
Lamb, Y. N. (2022) · Drugs · doi:10.1007/s40265-022-01692-5 · Cited by 319 · see citing works
Xu, Z., Shi, D., Han, J.-B., Ling, Y., Jiang, X., Lu, X., Li, C., Gong, L., Ge, G., Zhang, Y., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01429-0 · Cited by 303 · see citing works
Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01586-0 · Cited by 299 · see citing works
Acute graft-versus-host disease
Malard, F., Holler, E., Sandmaier, B. M., Huang, H., & Mohty, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00438-1 · Cited by 290 · see citing works
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2
Uraki, R., Kiso, M., Iida, S., Imai, M., Takashita, E., Kuroda, M., Halfmann, P., Loeber, S. J., Maemura, T., Yamayoshi, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04856-1 · Cited by 277 · see citing works
Modeling transmission of SARS-CoV-2 Omicron in China
Cai, J., Deng, X., Yang, J., Sun, K., Liu, H., Chen, Z., Peng, C., Chen, X., Wu, Q., Zou, J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01855-7 · Cited by 275 · see citing works
Recent advances in regenerative biomaterials
Cao, D., & Ding, J. (2022) · Regenerative Biomaterials · doi:10.1093/rb/rbac098 · Cited by 274 · see citing works
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C. W., Pozniak, A., Boffito, M., Waters, L. J., Burger, D. M., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2646 · Cited by 273 · see citing works
Wong, C. K. H., Au, I. C. H., Lau, K. T. K., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00507-2 · Cited by 269 · see citing works
The development of COVID-19 treatment
Yuan, Y., Jiao, B., Qu, L., Yang, D., & Liu, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125246 · Cited by 251 · see citing works
Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19.
Bramante, C. T., Huling, J. D., Tignanelli, C. J., Buse, J. B., Liebovitz, D. M., Nicklas, J. M., Cohen, K., Puskarich, M. A., Belani, H. K., Proper, J. L., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201662 · Cited by 242 · see citing works
VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
Cao, Z., Gao, W., Bao, H., Feng, H., Mei, S., Chen, P., Gao, Y., Cui, Z., Zhang, Q., Meng, X., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208822 · Cited by 236 · see citing works
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
Boby, M. L., Fearon, D., Ferla, M., Filep, M., Koekemoer, L., Robinson, M. C., Chodera, J. D., Lee, A. A., London, N., von Delft, A., et al. (2023) · Science · doi:10.1126/science.abo7201 · Cited by 231 · see citing works
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture system
Zhou, Y., Gammeltoft, K. A., Ryberg, L. A., Pham, L. V., Tjørnelund, H. D., Binderup, A., Hernandez, C. R. D., Fernandez-Antunez, C., Offersgaard, A., Fahnøe, U., et al. (2022) · Science Advances · doi:10.1126/sciadv.add7197 · Cited by 227 · see citing works
Montgomery, H., Hobbs, R. F., Padilla, F., Arbetter, D. F., Templeton, A., Seegobin, S., Kim, K., Campos, J. A. S., Arends, R. H., Brodek, B. H., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00180-1 · Cited by 218 · see citing works
Bhimraj, A., Morgan, R. L., Shumaker, A. H., Baden, L. R., Cheng, V. C., Edwards, K. M., Gallagher, J. C., Gandhi, R. T., Muller, W. J., Nakamura, M., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac724 · Cited by 215 · see citing works
Havers, F. P., Pham, H., Taylor, C. A., WHITAKER, M. D., Patel, K., Anglin, O., Kambhampati, A. K., Milucky, J., Zell, E. R., Moline, H. L., et al. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2022.4299 · Cited by 195 · see citing works
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Duan, Y., Zhou, H., Liu, X., Iketani, S., Lin, M.-M., Zhang, X., Bian, Q., Wang, H., Sun, H., Hong, S. J., et al. (2023) · Nature · doi:10.1038/s41586-023-06609-0 · Cited by 193 · see citing works
Jochmans, D., Liu, C., Donckers, K., Stoycheva, A. D., Boland, S., Stevens, S., Vita, C. D., Vanmechelen, B., Maes, P., Trüeb, B. S., et al. (2023) · mBio · doi:10.1128/mbio.02815-22 · Cited by 192 · see citing works
Dryden-Peterson, S., Kim, A., Kim, A. Y., Caniglia, E. C., Lennes, I. T., Patel, R., Gainer, L., Dutton, L., Donahue, E., Gandhi, R. T., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2141 · Cited by 182 · see citing works
Leng, A., Shah, M. M., Ahmad, S. A., Premraj, L., Wildi, K. S., Bassi, G. L., Pardo, C. A., Choi, A., & Cho, S. (2023) · Cells · doi:10.3390/cells12050816 · Cited by 180 · see citing works
Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
Hashemian, S. M. R., Sheida, A., Taghizadieh, M., Memar, M. Y., Hamblin, M. R., Baghi, H. B., Nahand, J. S., Asemi, Z., & Mirzaei, H. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114367 · Cited by 179 · see citing works
Singh, R. S. P., Toussi, S. S., Hackman, F., Chan, P. L., Rao, R. P., Allen, R., Eyck, L. V., Pawlak, S., Kadar, E. P., Clark, F., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2603 · Cited by 163 · see citing works
Therapeutic advances in COVID-19
Murakami, N., Hayden, R., Hills, T. E., Al-Samkari, H. T., Casey, J. D., Sorbo, L. D., Lawler, P. R., Sise, M. E., & Leaf, D. E. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00642-4 · Cited by 161 · see citing works
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Sakaguchi, H., Sonoyama, T., Ichihashi, G., Sanaki, T., Baba, K., Tsuge, Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac933 · Cited by 153 · see citing works
Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
Charness, M. E., Gupta, K., Stack, G. E., Strymish, J. M., Adams, E., Lindy, D. C., Mohri, H., & Ho, D. D. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206449 · Cited by 151 · see citing works
Oral Nirmatrelvir and Ritonavir in Nonhospitalized Vaccinated Patients With Coronavirus Disease 2019
Ganatra, S., Dani, S. S., Ahmad, J., Kumar, A., Shah, J., Abraham, G. M., McQuillen, D. P., Wachter, R. M., & Sax, P. E. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac673 · Cited by 148 · see citing works
Lewnard, J. A., McLaughlin, J. M., Malden, D. E., Hong, V. X., Puzniak, L., Ackerson, B. K., Lewin, B. J., Kim, J. S., Shaw, S. F., Takhar, H. S., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00118-4 · Cited by 146 · see citing works
Amani, B., & Amani, B. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28441 · Cited by 144 · see citing works
COVID-19 in patients with hematologic malignancy
Langerbeins, P., & Hallek, M. J. (2022) · Blood · doi:10.1182/blood.2021012251 · Cited by 141 · see citing works
Aggarwal, N. R., Molina, K. C., Beaty, L. E., Bennett, T. D., Carlson, N. E., Mayer, D. A., Peers, J. L., Russell, S., Wynia, M. K., & Ginde, A. A. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00011-7 · Cited by 139 · see citing works
Li, J., Zhou, Y., Ma, J., Zhang, Q., Shao, J., Liang, S., Yu, Y., Li, W., & Wang, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01640-z · Cited by 139 · see citing works
Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19
Hammond, J., Fountaine, R. J., Yunis, C., Fleishaker, D. L., Almas, M., Bao, W., Wisemandle, W., Baniecki, M. L., Hendrick, V. M., Kalfov, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309003 · Cited by 138 · see citing works
Self-citationPaxlovid: Mechanism of Action, Synthesis, and In Silico Study
Marzi, M., Vakil, M. K., Bahmanyar, M., & Zarenezhad, E. (2022) · BioMed Research International · doi:10.1155/2022/7341493 · Cited by 137 · see citing works
Mukae, H., Yotsuyanagi, H., Ohmagari, N., Doi, Y., Imamura, T., Sonoyama, T., Fukuhara, T., Ichihashi, G., Sanaki, T., Baba, K., et al. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00697-22 · Cited by 137 · see citing works
Bajema, K. L., Berry, K., Streja, E., Rajeevan, N., Li, Y., Mutalik, P., Yan, L., Cunningham, F. E., Hynes, D. M., Rowneki, M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-3565 · Cited by 134 · see citing works
Joyce, R., Hu, V. W., & Wang, J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02951-6 · Cited by 133 · see citing works
SARS-CoV-2 in immunocompromised individuals
DeWolf, S., Laracy, J. C., Perales, M., Kamboj, M., van den Brink, M. R. M., & Vardhana, S. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.09.006 · Cited by 132 · see citing works
Impact of COVID-19 on Cardiovascular Disease
Vosko, I., Zirlik, A., & Bugger, H. (2023) · Viruses · doi:10.3390/v15020508 · Cited by 129 · see citing works
The Mechanism-Based Inactivation of CYP3A4 by Ritonavir: What Mechanism?
Loos, N. H. C., Beijnen, J. H., & Schinkel, A. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179866 · Cited by 128 · see citing works
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19
Yotsuyanagi, H., Ohmagari, N., Doi, Y., Yamato, M., Bắc, N. H., Cha, B. K., Imamura, T., Sonoyama, T., Ichihashi, G., Sanaki, T., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.54991 · Cited by 128 · see citing works
Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection
Geng, L. N., Bonilla, H. F., Hedlin, H., Jacobson, K. B., Tian, L., Jagannathan, P., Yang, P. C.-M., Subramanian, A. K., Liang, J. W., Shen, S., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2024.2007 · Cited by 126 · see citing works
Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro
Hou, N., Shuai, L., Zhang, L., Xie, X., Tang, K., Zhu, Y., Yin, Y., Zhang, W., Tan, Q., Zhong, G., et al. (2023) · ACS Central Science · doi:10.1021/acscentsci.2c01359 · Cited by 122 · see citing works
Cesaro, S., Ljungman, P. T., Mikulska, M., Hirsch, H. H., von Lilienfeld‐Toal, M., Cordonnier, C., Meylan, S., Mehra, V., Styczyński, J., Marchesi, F., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01578-1 · Cited by 118 · see citing works
Small molecules in the treatment of COVID-19
Lei, S., Chen, X., Wu, J., Duan, X., & Men, K. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01249-8 · Cited by 117 · see citing works
Ip, J. D., Chu, A. W., Chan, W.-M., Leung, R. C.-Y., Abdullah, S. M., Sun, Y., & To, K. K. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104559 · Cited by 117 · see citing works
Wang, S., Li, W., Wang, Z., Yang, W., Li, E., Xia, X., Yan, F., & Chiu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01917-x · Cited by 117 · see citing works
Vaccines and therapeutics for immunocompromised patients with COVID-19
Shoham, S., Batista, C., Amor, Y. B., Ergönül, Ö., Hassanain, M. M., Hotez, P. J., Kang, G., Kim, J. H., Lall, B., Larson, H. J., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101965 · Cited by 116 · see citing works
Toussi, S. S., Hammond, J., Gerstenberger, B. S., & Anderson, A. S. (2023) · Nature Microbiology · doi:10.1038/s41564-023-01356-4 · Cited by 112 · see citing works
Self-citationSasaki, M., Tabata, K., Kishimoto, M., Itakura, Y., Kobayashi, H., Ariizumi, T., Uemura, K., Toba, S., Kusakabe, S., Maruyama, Y., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq4064 · Cited by 108 · see citing works
Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
Anderson, A. S., Caubel, P., & Rusnak, J. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2205944 · Cited by 105 · see citing works
Self-citationWai, A. K. C., Chan, C. Y., Cheung, A. W.-L., Wang, K., Chan, S. C. L., Lee, T. T.-L., Luk, L. Y. F., Yip, T. F., Ho, J. W. K., Tsui, O. W.-K., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100602 · Cited by 105 · see citing works
Liu, J., Pan, X., Zhang, S., Li, M., Ma, K., Fan, C., Lv, Y., Guan, X., Yang, Y., Ye, X., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100694 · Cited by 105 · see citing works
Naggie, S., Boulware, D. R., Lindsell, C. J., Stewart, T. G., Gentile, N., Collins, S. P., McCarthy, M. W., Jayaweera, D. T., Castro, M., Sulkowski, M., et al. (2022) · JAMA · doi:10.1001/jama.2022.18590 · Cited by 102 · see citing works
Shah, M. M., Joyce, B., Plumb, I. D., Sahakian, S., Feldstein, L. R., Barkley, E., Paccione, M., Deckert, J., Sandmann, D., Gerhart, J. L., et al. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7148e2 · Cited by 102 · see citing works
FDA approved fluorine-containing drugs in 2023
Wang, Q., Bian, Y., Dhawan, G., Zhang, W., Sorochinsky, A. E., Makarem, A., Soloshonok, V. A., & Han, J. (2024) · Chinese Chemical Letters · doi:10.1016/j.cclet.2024.109780 · Cited by 102 · see citing works
Chung, Y.-S., Lam, C.-Y., Tan, P.-H., Tsang, H. F., & Wong, S. C. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158155 · Cited by 100 · see citing works
Schwartz, K. L., Wang, J., Tadrous, M., Langford, B. J., Daneman, N., Leung, V., Gomes, T., Friedman, L., Daley, P., & Brown, K. A. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.221608 · Cited by 99 · see citing works
Yip, T. C., Lui, G. C.-Y., Lai, M. S., Wong, V. W., Tse, Y. K., Ma, B. H.-M., Hui, E., Leung, M. K., Chan, H. L., Hui, D. S.-C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac687 · Cited by 98 · see citing works
Allerton, C. M. N., Arcari, J. T., Aschenbrenner, L. M., Avery, M., Bechle, B. M., Behzadi, M. A., Boras, B. W., Buzon, L. M., Cardin, R. D., Catlin, N. R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02469 · Cited by 95 · see citing works
Mathian, A., Breillat, P., Dorgham, K., Bastard, P., Charre, C., Lhote, R., Quentric, P., Moyon, Q., Mariaggi, A., Mouries-Martin, S., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-222549 · Cited by 94 · see citing works
Li, X., & Song, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115772 · Cited by 93 · see citing works
Schilling, W. H., Jittamala, P., Watson, J. A., Boyd, S., Luvira, V., Siripoon, T., Ngamprasertchai, T., Batty, E. M., Cruz, C. V., Callery, J. J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00493-0 · Cited by 91 · see citing works
Oral antiviral treatments for COVID-19: opportunities and challenges
Rahmah, L., Abarikwu, S. O., Arero, A. G., Essouma, M., Jibril, A. T., Fal, A., Flisiak, R., Makuku, R., Marquez, L. P., Mohamed, K., et al. (2022) · Pharmacological Reports · doi:10.1007/s43440-022-00388-7 · Cited by 88 · see citing works
Cognitive dysfunction in post‐COVID‐19 condition: Mechanisms, management, and rehabilitation
Möller, M. C., Borg, K., Janson, C., Lerm, M., Normark, J., & Niward, K. (2023) · Journal of Internal Medicine · doi:10.1111/joim.13720 · Cited by 87 · see citing works
COVID-19 drug discovery and treatment options
Chan, J. F., Yuan, S., Chu, H., Sridhar, S., & Yuen, K. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01036-y · Cited by 87 · see citing works
Radcliffe, C. V., Palacios, C. F., Azar, M. M., Cohen, E., & Malinis, M. F. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17098 · Cited by 85 · see citing works
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs
Bastard, P., Vazquez, S. E., Liu, J., Laurie, M. T., Wang, C., Gervais, A., Voyer, T. L., Bizien, L., Zamecnik, C. R., Philippot, Q., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abp8966 · Cited by 85 · see citing works
Dufour, J., Marjot, T., Becchetti, C., & Tilg, H. (2022) · Gut · doi:10.1136/gutjnl-2021-326792 · Cited by 85 · see citing works
Boucau, J., Uddin, R., Marino, C., Regan, J., Flynn, J. P., Choudhary, M. C., Chen, G., Stuckwisch, A. M., Mathews, J., Liew, M. Y., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac512 · Cited by 85 · see citing works
Thromboinflammation in long COVID—the elusive key to postinfection sequelae?
Nicolai, L., Kaiser, R. W. J., & Stark, K. (2023) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2023.04.039 · Cited by 85 · see citing works
Marjot, T., Eberhardt, C. S., Boettler, T., Belli, L. S., Berenguer, M., Buti, M., Jalan, R., Mondelli, M. U., Moreau, R., Shouval, D., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.07.008 · Cited by 84 · see citing works
Lu, G., Zhang, Y., Zhang, H., Ai, J., He, L., Yuan, X., Bao, S., Chen, X., Wang, H., Cai, J., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2109517 · Cited by 84 · see citing works
Efficacy and safety of Paxlovid for COVID-19:a meta-analysis
Zheng, Q., Ma, P., Wang, M., Cheng, Y., Zhou, M., Ye, L., Feng, Z., & Zhang, C. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.09.027 · Cited by 84 · see citing works
Chen, P., Tang, G., Zhu, C., Sun, J., Wang, X., Xiang, M., Huang, H., Wang, W., Li, L., Zhang, Z., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11595 · Cited by 84 · see citing works
Carlin, A. F., Clark, A. E., Chaillon, A., Garretson, A. F., Bray, W. A., Porrachia, M., Santos, A. T., Rana, T. M., & Smith, D. M. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac496 · Cited by 81 · see citing works
Zhong, W., Yang, Z., & Chen, C. Y. (2023) · Nature Communications · doi:10.1038/s41467-023-38851-5 · Cited by 81 · see citing works
Cardiovascular disease as part of Long COVID: a systematic review
Tsampasian, V., Bäck, M., Bernardi, M., Cavarretta, E., Dębski, M., Gati, S., Hansen, D., Kränkel, N., Koskinas, K. C., Niebauer, J., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae070 · Cited by 79 · see citing works
Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection
Deo, R., Choudhary, M. C., Moser, C., Ritz, J., Daar, E. S., Wohl, D. A., Greninger, A. L., Eron, J. J., Currier, J. S., Hughes, M. D., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2381 · Cited by 77 · see citing works
Hirotsu, Y., Kobayashi, H., Kakizaki, Y., Saito, A., Tsutsui, T., Kawaguchi, M., Shimamura, S., Hata, K., Hanawa, S., Toyama, J., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.001 · Cited by 77 · see citing works
Zhou, H., Møhlenberg, M., Thakor, J. C., Tuli, H. S., Wang, P., Assaraf, Y. G., Dhama, K., & Jiang, S. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00014-22 · Cited by 76 · see citing works
Arockiaraj, M., Greeni, A. B., & Kalaam, A. R. A. (2023) · International Journal of Quantum Chemistry · doi:10.1002/qua.27136 · Cited by 76 · see citing works
Synthetic Gene Circuits for Regulation of Next‐Generation Cell‐Based Therapeutics
Teixeira, A. P., & Fussenegger, M. (2023) · Advanced Science · doi:10.1002/advs.202309088 · Cited by 76 · see citing works
Pathophysiological, immunological, and inflammatory features of long COVID
Böhmwald, K., Diethelm‐Varela, B., Rodríguez‐Guilarte, L., Rivera, T., Riedel, C. A., González, P. A., & Kalergis, A. M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1341600 · Cited by 75 · see citing works
SARS-CoV-2 Virologic Rebound With Nirmatrelvir–Ritonavir Therapy
Edelstein, G. E., Boucau, J., Uddin, R., Marino, C., Liew, M. Y., Barry, M., Choudhary, M. C., Gilbert, R. F., Reynolds, Z., Li, Y., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m23-1756 · Cited by 74 · see citing works
Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents
Zagórska, A., Czopek, A., Fryc, M., & Jończyk, J. (2024) · Biomolecules · doi:10.3390/biom14070797 · Cited by 74 · see citing works
Viral proteases as therapeutic targets
Majerová, T., & Konvalinka, J. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101159 · Cited by 73 · see citing works
Kertes, J., David, S. S. B., Engel-Zohar, N., Rosen, K., Hemo, B., Kantor, A., Adler, L., Shamir-Stein, N., Reuveni, M. M., & Shahar, A. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac625 · Cited by 72 · see citing works
Long COVID: Costs for the German economy and health care and pension system
Gandjour, A. (2023) · BMC Health Services Research · doi:10.1186/s12913-023-09601-6 · Cited by 72 · see citing works
Herrera, D., & Campos, G. D. L. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07262-0 · Cited by 71 · see citing works
- Authors
- Hammond, J., Leister-Tebbe, H., Gardner, A., Abreu, P., Bao, W., Wisemandle, W., Baniecki, M., Hendrick, V. M., Damle, B., Simón-Campos, A., Pypstra, R., & Rusnak, J. M.
- Affiliations
- Pfizer (United States) (US)
- From Global Product Development, Pfizer, Collegeville, PA (J.H., H.L.-T.); Global Product Development (A.G.) and Early Clinical Development (M.L.B.), Pfizer, Cambridge, MA; Global Product Development, Pfizer, New York (P.A., W.B., B.D., R.P.); Global Product Development, Pfizer, Lake Forest, IL (W.W.); Medical and Safety, Pfizer, Sandwich, United Kingdom (V.M.H.); Köhler and Milstein Research, Mérida, Yucatan, Mexico (A.S.-C.); and Global Product Development, Pfizer, Tampa, FL (J.M.R.).
- Corresponding author
- Hammond, Jennifer
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-04-14
- Volume
- 386
- Issue
- 15
- Pages
- 1397-1408
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8908851
- OpenAlex
- W4212904481
- Cited by
- 2,323
- References
- 21
- Citations by year
- 2026: 186 · 2025: 319 · 2024: 517 · 2023: 769 · 2022: 525 · 2020: 2
- FWCI
- 261.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
- Keywords
- nirmatrelvir, COVID-19 pandemic, SARS-CoV-2, Mpro inhibitors, ritonavir, oral antiviral therapy, high-risk adults, non-hospitalized patients, viral load, unvaccinated patients, early treatment, SARS-CoV-2 variants, Omicron variant
- MeSH terms
- Viral Protease Inhibitors, COVID-19, SARS-CoV-2, COVID-19 Drug Treatment, Administration, Oral, Adult, Antiviral Agents, Double-Blind Method, Drug Combinations, Hospitalization, Humans, Lactams, Leucine, Nitriles, Proline, Vaccination, Treatment Outcome, Disease Progression, Ritonavir, Viral Load
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
